A large-scale real-world study has found that GLP-1 receptor agonist medications — the drug class behind popular treatments like semaglutide — significantly reduce the risk of major cardiovascular events and end-stage kidney disease in people with type 1 diabetes. The analysis, which examined data from 174,678 patients over five years, represents one of the most comprehensive assessments to date of GLP-1 drugs in this population. Researchers say the findings could reshape how clinicians approach adjunctive therapy for type 1 diabetes management.
Using a target trial emulation methodology, investigators compared outcomes in type 1 diabetes patients who initiated GLP-1 receptor agonist therapy against those who did not. The study found statistically meaningful reductions in major adverse cardiovascular events, including heart attack and stroke, as well as a lower incidence of end-stage kidney disease among those who received the drugs. Patients on GLP-1 therapy also demonstrated notable improvements in body weight and glycemic control over the follow-up period.
A key concern surrounding the use of GLP-1 receptor agonists in type 1 diabetes has been the potential for increased risk of diabetic ketoacidosis, a serious and potentially life-threatening complication more prevalent in this patient group than in type 2 diabetes. The study found no significant increase in hospitalizations for diabetic ketoacidosis or severe hypoglycemia among GLP-1 users, a finding researchers described as reassuring. This safety profile strengthens the case for conducting dedicated randomized controlled trials to further evaluate GLP-1 drugs as an add-on therapy in type 1 diabetes management.
GLP-1 receptor agonists have already demonstrated substantial cardiovascular and renal benefits in patients with type 2 diabetes, driving widespread adoption across that patient population in recent years. However, their use in type 1 diabetes has remained limited and largely off-label, partly due to safety concerns and a lack of large-scale clinical trial data in this group. The new analysis, drawing on real-world patient records, offers the most extensive evidence yet that the benefits observed in type 2 diabetes may extend to people living with type 1.
Researchers emphasized that while the findings are compelling, target trial emulation studies carry inherent limitations compared to randomized controlled trials, including the potential for residual confounding. They called for prospective randomized trials to confirm the cardiovascular and renal protective effects of GLP-1 receptor agonists specifically in type 1 diabetes populations. If validated, the results could support regulatory and clinical guideline changes that expand access to these treatments for the approximately 8 to 9 million people worldwide estimated to be living with type 1 diabetes.
